As of November 6, 2026, Alamar Biosciences, Inc. is a publicly traded company (Nasdaq: ALMR). The largest holder reporting an active stake on Schedule 13D is Illumina Innovation Fund II, L.P., at 9.6%. No bankruptcy or receivership appears in its SEC Form 8-K filings. Founder or officer holdings: Yuling Luo, the chief executive and a director (6.4%, reporting on Schedule 13G) (Schedule 13D, April 23, 2026).
Is this your company?
About to sign with, pay or invest in Alamar Biosciences, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Alamar Biosciences, Inc. a real, registered company?
- Alamar Biosciences, Inc. files with the SEC under CIK 2104204 (its SEC filings).
- Its shares are listed under the ticker ALMR on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Fremont, California, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Alamar Biosciences, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Leadership changes: the latest reported is Robert Ragusa, Director (Form 8-K filed 2026-09-01). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Yuling Luo (filed 2026-08-13).
Who are Alamar Biosciences, Inc.'s owners and officers?
Alamar Biosciences, Inc.: incorporated in Delaware; business address in Fremont, California; industry Laboratory Analytical Instruments (Form D, 2026-09-01).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G, 2026-08-13 | Yuling Luo | 6.4% |
| Schedule 13G, 2026-08-11 | Qiming Corporate Gp Vi, LTD | 10.2% |
| Schedule 13D/A, 2026-07-07 | Sands Capital Life Sciences Pulse Fund Ii, L.P. | 6.1% |
| Schedule 13G, 2026-07-02 | Daqing Cai | 7.2% |
| Schedule 13D, 2026-04-23 | Sands Capital Life Sciences Pulse Fund Ii, L.P. | 6.3% |
| Schedule 13D, 2026-04-23 | Illumina Innovation Fund Ii, L.P. | 9.6% |
Questions about who owns Alamar Biosciences, Inc.
Who owns Alamar Biosciences, Inc.?
On this page, 5 holders' latest ownership filings report 5% or more of Alamar Biosciences, Inc.: Qiming Corporate Gp Vi, LTD (10.2%, Schedule 13G, filed 2026-08-11), Illumina Innovation Fund Ii, L.P. (9.6%, Schedule 13D, filed 2026-04-23), Daqing Cai (7.2%, Schedule 13G, filed 2026-07-02), Yuling Luo (6.4%, Schedule 13G, filed 2026-08-13) and Sands Capital Life Sciences Pulse Fund Ii, L.P. (6.1%, Schedule 13D/A, filed 2026-07-07).
Who are the largest shareholders of Alamar Biosciences, Inc.?
By the share each holder's latest filing reports, the largest holders of Alamar Biosciences, Inc. on this page are Qiming Corporate Gp Vi, LTD (10.2%), Illumina Innovation Fund Ii, L.P. (9.6%) and Daqing Cai (7.2%).
When did Qiming Corporate Gp Vi, LTD buy into Alamar Biosciences, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Qiming Corporate Gp Vi, LTD on this page is the Schedule 13G, filed 2026-08-11, reporting 10.2%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 6 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Alamar Biosciences, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Alamar Biosciences, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Alamar Biosciences, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
14 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-09-01 | Robert Ragusa | Director | appointed | 2026-09-01 |
| Form 8-K, 2026-09-01 | Robert Ragusa | appointed |
Which insiders own Alamar Biosciences, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief executive and a director: 3,164,726 shares (4.6% of shares outstanding), 1,940,574 held directly and 1,224,152 indirectly (Form 4, 2026-04-20).
- Qiming Managing Directors Fund VI, L.P., a 10% owner: 1,650,354 shares (2.4% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-11-05).
- Qiming Venture Partners VI, L.P., a 10% owner: 1,650,354 shares (2.4% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-11-05).
- Qiming Corporate GP VI, Ltd., a 10% owner: 1,650,354 shares (2.4% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-11-05).
- Qiming GP VIII, LLC, a 10% owner: 1,650,354 shares (2.4% of shares outstanding), held indirectly (the form names the holder only in its footnotes), on a joint filing (Form 4, 2026-11-05).
Shares outstanding: 69,481,651 as of 2026-10-31, from the company's latest SEC cover page.
How much has Alamar Biosciences, Inc. raised?
Latest IPO step: Alamar Biosciences, Inc. filed its final IPO prospectus, ticker ALMR (424B4, 2026-04-17).
IPO filings: 424B4, 2026-04-17, S-1/A, 2026-04-16, S-1/A, 2026-04-13, S-1, 2026-03-27; ticker ALMR on Nasdaq Global Select Market.
Keep reading
More on Alamar Biosciences, Inc. and the records around it.
Alamar Biosciences, Inc. elsewhere on the record
- Leadership changes Sep 2026
- 5%+ stake filings Aug 2026
Companies that share a holder
- Sands Capital Life Sciences Pulse Fund II, L.P. also filed stake reports on 3 other companies: Acrivon Therapeutics, Inc. (Aug 2026), Inhibikase Therapeutics, Inc. (Aug 2026), Beta Bionics, Inc. (Aug 2025)
Related pages
Leadership changes5%+ holdersIPO filings
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/alamar-biosciences